Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

Reardon, David A., Quinn, Jennifer A., Vredenburgh, James J., Gururangan, Sridharan, Friedman, Allan H., Desjardins, Annick, Sathornsumetee, Sith, Herndon, James E., Dowell, Jeannette M., McLendon, Roger E., Provenzale, James M., Sampson, John H., Smith, Robert P., Swaisland, Alan J., Ochs, Judith S., Lyons, Peggy, Tourt-Uhlig, Sandy, Bigner, Darell D., Friedman, Henry S., Rich, Jeremy N.·2006·Clinical Cancer Research

Abstract

Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent malignant glioma. Patients and Methods: Gefitinib and sirolimus were administered on a continuous daily dosing schedule at dose levels that were escalated in successive cohorts of malignant glioma patients at any recurrence who were stratified based on concurrent use of CYP3A-inducing anticonvulsants [enzyme-inducing antiepileptic drugs, (EIAED)]. Pharmacokinetic and archival tumor biomarker data were also assessed. Results: Thirty-four patients with progressive disease after prior radiation therapy and chemotherapy were enrolled, including 29 (85%) with glioblastoma multiforme and 5 (15%) with anaplastic glioma. The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs. DLTs included mucositis, diarrhea, rash, thrombocytopenia, and hypertriglyceridemia. Gefitinib exposure was not affected by sirolimus administration but was significantly lowered by concurrent EIAED use. Two patients (6%) achieved a partial radiographic response, and 13 patients (38%) achieved stable disease. Conclusion: We show that gefitinib plus sirolimus can be safely coadministered on a continuous, daily dosing schedule, and established the recommended dose level of these agents in combination for future phase 2 clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-2215

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 191

Metadata

Authors
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., Provenzale, J. M., Sampson, J. H., Smith, R. P., Swaisland, A. J., Ochs, J. S., Lyons, P., Tourt-Uhlig, S., Bigner, D. D., Friedman, H. S., & Rich, J. N.
Venue
Clinical Cancer Research
Published
2006-02-01
Volume
12
Issue
3
Pages
860-868
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2137551916
Cited by
191
References
6
FWCI
11.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2215
The paper
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., Provenzale, J. M., Sampson, J. H., Smith, R. P., Swaisland, A. J., Ochs, J. S., Lyons, P., Tourt-Uhlig, S., Bigner, D. D., Friedman, H. S., & Rich, J. N. (2006). Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2215

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.